Keflex contains cephalexin, a bactericidal antibiotic, and is registered in 22 countries spanning several continents. It is one of the longer-established cephalexin brands on the international market, familiar to clinicians and patients in markets as different as Australia, Brazil, Japan, Norway, and Egypt.
Cephalexin is prescribed in the management of a range of bacterial infections. The indications associated with Keflex across its registered markets include respiratory tract infections such as pneumonia, ear infections including chronic middle ear infection, urinary and prostate infections including acute prostatitis, and bone infections, among other bacterial conditions. The structured indication block further down this page lists each registered use as recognised by national regulators.
Because Keflex has a mid-sized international footprint, travellers and expatriates encounter it inconsistently — common in some pharmacies, absent in others. Markets where it is registered include Mexico, Ireland, Lebanon, Iceland, and Lithuania, but regulatory packaging, prescription pathways, and even product strength conventions differ from one country to another. Where Keflex itself is not stocked, cephalexin is widely available under other brand names, and a local pharmacist can usually identify the equivalent product on a regional formulary.
Other antibiotics in the broader bactericidal family — including other cephalosporins and unrelated classes — are also distributed worldwide under many brand names. Antibiotics, however, are not freely interchangeable: choice depends on the specific infection, local resistance patterns, patient history, and prescriber judgement. Anyone taking Keflex, being prescribed it abroad, or trying to identify a local cephalexin equivalent should treat that decision as a clinical one and speak with a healthcare provider familiar with their situation.
